EP1765852A4 - Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member - Google Patents

Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member

Info

Publication number
EP1765852A4
EP1765852A4 EP05714663A EP05714663A EP1765852A4 EP 1765852 A4 EP1765852 A4 EP 1765852A4 EP 05714663 A EP05714663 A EP 05714663A EP 05714663 A EP05714663 A EP 05714663A EP 1765852 A4 EP1765852 A4 EP 1765852A4
Authority
EP
European Patent Office
Prior art keywords
psp94
metastasis
composition
family member
preventing cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05714663A
Other languages
German (de)
French (fr)
Other versions
EP1765852A1 (en
Inventor
Chandra J Panchal
Jinzi Jason Wu
Richard Beliveau
Marcia Ruiz
Seema Garde
Borhane Annabi
Sylvie Lamy
Mounia Bouzeghrane
Luc Daigneault
Robert Hawkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrilia Biopharma Inc
Original Assignee
Ambrilia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/857,358 external-priority patent/US20050026833A1/en
Priority claimed from US10/948,229 external-priority patent/US20050096273A1/en
Priority claimed from US11/004,273 external-priority patent/US20050148514A1/en
Application filed by Ambrilia Biopharma Inc filed Critical Ambrilia Biopharma Inc
Publication of EP1765852A1 publication Critical patent/EP1765852A1/en
Publication of EP1765852A4 publication Critical patent/EP1765852A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP05714663A 2004-06-01 2005-03-21 Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member Withdrawn EP1765852A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/857,358 US20050026833A1 (en) 2001-11-08 2004-06-01 PSP-94: use for treatment of hypercalcemia and bone metastasis
US10/948,229 US20050096273A1 (en) 2003-09-26 2004-09-24 Regulation of matrix metalloproteinases by PSP94 family members
US11/004,270 US20050147601A1 (en) 2003-09-26 2004-12-02 Regulation of cell migration and adhesion
US11/004,273 US20050148514A1 (en) 2003-09-26 2004-12-02 Method and composition for treatment of angiogenesis
PCT/CA2005/000430 WO2005118623A1 (en) 2004-06-01 2005-03-21 Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member

Publications (2)

Publication Number Publication Date
EP1765852A1 EP1765852A1 (en) 2007-03-28
EP1765852A4 true EP1765852A4 (en) 2008-06-11

Family

ID=35462882

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05714663A Withdrawn EP1765852A4 (en) 2004-06-01 2005-03-21 Method and composition for treating angiogenesis and for preventing cancer progression and metastasis comprising a prostate secretory protein (psp94) family member

Country Status (5)

Country Link
EP (1) EP1765852A4 (en)
JP (1) JP2008501645A (en)
AU (1) AU2005250059A1 (en)
CA (1) CA2567901A1 (en)
WO (1) WO2005118623A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033141A1 (en) * 2003-09-26 2005-04-14 Ambrilia Biopharma Inc. Regulation of matrix metalloproteinases by psp94 family members

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355334A1 (en) * 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
CA2361736A1 (en) * 2001-11-08 2003-05-08 Unknown Psp 94: use for treatment of hypercalcemia and bone metastasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033141A1 (en) * 2003-09-26 2005-04-14 Ambrilia Biopharma Inc. Regulation of matrix metalloproteinases by psp94 family members

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BÉLIVEAU RICHARD ET AL: "The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH APR 2002, vol. 8, no. 4, April 2002 (2002-04-01), pages 1242 - 1250, XP002477717, ISSN: 1078-0432 *
GINGRAS DENIS ET AL: "Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins", BIOCHEMICAL JOURNAL, vol. 348, no. 2, 1 June 2000 (2000-06-01), pages 273 - 280, XP002477718, ISSN: 0264-6021 *
LAMY SYLVIE ET AL: "A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis", INTERNATIONAL JOURNAL OF CANCER, vol. 118, no. 9, May 2006 (2006-05-01), pages 2350 - 2358, XP002477719, ISSN: 0020-7136 *
LAMY SYLVIE ET AL: "Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation", CANCER RESEARCH, vol. 62, no. 2, 15 January 2002 (2002-01-15), pages 381 - 385, XP002477716, ISSN: 0008-5472 *
See also references of WO2005118623A1 *

Also Published As

Publication number Publication date
CA2567901A1 (en) 2005-12-15
JP2008501645A (en) 2008-01-24
AU2005250059A1 (en) 2005-12-15
EP1765852A1 (en) 2007-03-28
WO2005118623A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
GB2435063B (en) Sand control completion having smart well capability and method for use of same
SG133592A1 (en) Methods for treating prostate cancer with herbal compositions
AU2003294205A8 (en) Prostate cancer biomarkers
EP1697497A4 (en) Liver cancer biomarkers
IL179095A0 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
PL1766017T3 (en) Tumor specific antibody
HK1077583A1 (en) Cudr as biomarker for cancer progression and therapeutic response
IL179059A0 (en) Method of diagnosing prostate cancer
IL179812A0 (en) THE IMPORTANCE OF THE GENE HoxB13 FOR CANCER
EP1824520A4 (en) Methods of detecting prostate cancer
PL1781449T3 (en) Method of centerless grinding
SG118403A1 (en) Wafer dividing method
IL176919A0 (en) Methods and compositions for treating cancer
EP1680073A4 (en) Compounds and method for treating cancer
EP1755394A4 (en) Cancer treatment method
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
GB2411416B (en) Flow diversion apparatus and method
ZA200705059B (en) Cancer treatment method
HK1087244A1 (en) Ferrite magnetic material and method for producinghexagonal w type ferrite magnetic material
IL179323A0 (en) Cancer treatment method
EP1622674A4 (en) Method for treating glandular diseases and malignancies
EP1599572A4 (en) Compositions and methods for cancer immunotherapy
GB0417740D0 (en) Methods and kit for the prognosis of breast cancer
IL179359A0 (en) Cancer treatment method
EP1783231A4 (en) Method of judging grade of malignancy of carcinoma cell

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

A4 Supplementary search report drawn up and despatched

Effective date: 20080515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080814